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Abstract
Cancer cells are characterized by metabolic alterations, namely, depressed mitochondrial
oxidation, enhanced glycolysis and pentose phosphate shunt flux to support rapid cell
growth, which is called the Warburg effect. In our study we assessed the metabolic conse-
quences of a joint treatment of MCF-7 breast cancer cells with AICAR, an inducer of AMP-
activated kinase (AMPK) jointly with methotrexate (MTX), a folate-analog antimetabolite
that blunts de novo nucleotide synthesis. MCF7 cells, a model of breast cancer cells, were
resistant to the individual application of AICAR or MTX, however combined treatment of
AICAR and MTX reduced cell proliferation. Prolonged joint application of AICAR and MTX
induced AMPK and consequently enhanced mitochondrial oxidation and reduced the rate
of glycolysis. These metabolic changes suggest an anti-Warburg rearrangement of metabo-
lism that led to the block of the G1/S and the G2/M transition slowing down cell cycle. The
slowdown of cell proliferation was abolished when mitotropic transcription factors, PGC-1α,
PGC-1β or FOXO1 were silenced. In human breast cancers higher expression of AMPKα
and FOXO1 extended survival. AICAR and MTX exerts similar additive antiproliferative
effect on other breast cancer cell lines, such as SKBR and 4T1 cells, too. Our data not only
underline the importance of Warburg metabolism in breast cancer cells but nominate the
AICAR+MTX combination as a potential cytostatic regime blunting Warburg metabolism.
Furthermore, we suggest the targeting of AMPK and FOXO1 to combat breast cancer.
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Introduction
Cancer cells, among them, breast cancer cells undergo marked metabolic changes upon trans-
formation that is called Warburg metabolism characterized by enhanced glycolysis and
reduced mitochondrial oxidation [1]. Tumor cells are hypermetabolic and utilize external (glu-
cose, glutamine) and internal (glycogen) substrates extensively [1–3]. Glucose degradation
(both from external and internal source) through glycolysis is the major ATP source of tumor
cells, therefore glycolytic rate is increased in tumors [3]. Furthermore, enhanced glycolysis
boost the pentose-phosphate shunt that is vital for de novo nucleotide production [1]. Mean-
while, mitochondria, through expressing an alternative enzyme set utilizes glutamine to supply
cells with vital intermediates (e.g. citrate for fatty acid synthesis) to support extensive rate of
cell division [1]. Importantly, the G1/S checkpoint in cell cycle is under metabolic control, cell
cycle is blocked if the metabolite pool, necessary for successful DNA replication, is missing
[4,5].
The accommodation of cellular metabolism is regulated through an intricate web of stress
sensors involving AMP-activated kinase (AMPK). AMPK is activated by increases in cellular
ATP/AMP ratio [6]. Increases in the ATP/AMP ratio reflect decreases in cellular energy charge
and in response to that, AMPK induces catabolic and, simultaneously, reduces anabolic pro-
cesses [6]. AMPK is in intricate relations with other energy/metabolite sensor pathways (e.g.
SIRT1, Akt, mTOR, PARPs, etc.) and act in a coordinate fashion with those [3,6–9]. AMPK
induction leads to enhanced mitochondrial oxidation and mitochondrial biogenesis that had
been shown to exert anti-Warburg and antiproliferative effects in lymphomas [10]. In our stud-
ies we utilized 5-Aminoimidazole-4-carboxamide 1-β-D-ribofuranoside (AICAR) to pharma-
cologically induce AMPK [11].
Breast cancer is one the most frequent tumor among women worldwide and despite exten-
sive prevention programs, still represent a major cause of mortality. Treatment options involve
surgical excision of the tumor tissue and chemotherapy [12]. Methotrexate (MTX) is not con-
sidered as a first-line agent in chemotherapy of breast cancer, it is used in combination with
cyclophosphamide and 5-fluoro-uracil that is termed the CMF regime [12]. MTX primarily
targets de novo nucleotide synthesis by interfering with the folate-dependent 1 carbon metabo-
lism. Breast cancer cells are characterized by Warburg rearrangement [13–16], furthermore,
attempts to revert Warburg metabolism (also called an anti-Warburg rearrangement of metab-
olism) support chemotherapy [17]. The apparent importance of Warburg metabolism in breast
cancer cells suggested that AMPK activation and the following metabolic rearrangements may
have antiproliferative effects and may act synergistically with methotrexate.
Methods
Chemicals
All chemicals were from Sigma-Aldrich if not stated otherwise. For the pharmacological activa-
tion of AMPK, AICAR was used (Sigma-Aldrich or Santa Cruz Biotech).
Cell Culture
MCF-7 cells—a generous gift from Dr. Árpád Lányi (Department of Immunology, University
of Debrecen, Debrecen, Hungary)—were maintained in MEM (Sigma-Aldrich), 10% fetal
bovine serum (Sigma-Aldrich), 1% Penicillin/Streptomycin (Invitrogene), 2 mM L-Glutamine.
MCF-7 cells were treated with 100 μMAICAR and 10 μMMTX and AICAR+MTX as indi-
cated through one or six days. Cells were harvested for further analysis at day one and six. Con-
trol cells were cultured in the same media and treated with vehicle (PBS).
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SKBR-3 cells—a generous gift from Dr. Péter Nagy (Department of Biophysics and Cell
Biology, University of Debrecen, Debrecen, Hungary)—were maintained in MEM (Sigma-
Aldrich), 10% fetal bovine serum (Sigma-Aldrich), 1% Penicillin/Streptomycin (Invitrogene),
2 mM L-Glutamine. SKBR-3 cells were treated with 100 μMAICAR and 10 μMMTX and
AICAR+MTX as indicated through three days. Cells were harvested for further analysis at day
three. Control cells were cultured in the same media and treated with vehicle (PBS).
4T1 cells—a generous gift from Dr. Ferenc Gallyas Jr. (Department of Biochemistry, Uni-
versity of Pécs, Pécs, Hungary)—were maintained in MEM (Sigma-Aldrich), 10% fetal bovine
serum (Sigma-Aldrich), 1% Penicillin/Streptomycin (Invitrogene), 2 mM L-Glutamine. 4T1
cells were treated with 300 μMAICAR, 7.8 nMMTX and 300 μMAICAR+7.8 nMMTX as
indicated through two days. Cells were harvested for further analysis at day two. Control cells
were cultured in the same media and treated with vehicle (PBS).
SAOS cells were cultured in DMEMmedium(SIGMA Aldrich) supplemented with 10% foe-
tal bovine serum (FBS), 2mM L-glutamine, and 0,5% penicillin/streptomycin in humidified
atmosphere 95%air-5% CO2 at 37C. Cell were passaged in every third day by Trypsin/EDTA
(SIGMA Aldrich).
WM35 cells were maintained in RPMI-1640 medium supplemented with 10%foetal bovine
serum (FBS), 2mM L-glutamine, and 0,5% penicillin/streptomycin in humidified atmosphere
95%air-5% CO2 at 37C. Cell were passaged in every third day by Trypsin/EDTA (SIGMA
Aldrich).
The cell lines used in the study are available from European Collection of Authenticated
Cell Cultures (ECACC).
Cell cycle analysis
Cell cycle analysis was performed as described in [18]. MCF-7 cells were seeded in 6-well plate
(10 000 cells/well). Cell cycle analysis of AICAR, MTX and AICAR+MTX treated cells were
carried out following fixation in 70% ethanol and staining with 50 μg/ml propidium iodide (PI)
using FACSCalibur. The acquired data were processed with the BD CellQuest™ Pro. software
(Beckton Dickinson, Mountain View, CA).
Sulphorhodamine B assay
In order to detect growth inhibition sulphoradamine B (SRB) assay that measures changes in
total protein content was applied. Cells were seeded in 96-well plate (3000–5000 cells/well).
Cells were grown in the presence of vehicle, AICAR, MTX, AICAR+MTX for the time indi-
cated (MCF-7 cells– 6 days, SKBR-3 cells– 3 days, 4T1 cells– 2 days, SAOS cells– 6 days,
WM35–6 days). Cells were checked in an invert microscope every day. At the end of the treat-
ment, after fixation in situ by 50% trichloroacetic acid (TCA) cell were stained with sulforhoda-
mine B (SRB) solution (0.4% in 1% acetic acid). Unbound dye was removed by washing with
1% acetic acid. Bound stain was solubilized with 10 mM TRIS base. Absorbance was read on an
automated plate reader (Thermo Labsystems Multiskan MS) at 540 nm.
Cell death assays
Caspase and propidium-iodide uptake assays were performed as described in [19].
SDS-PAGE andWestern Blotting
Sample preparation, protein separation, transfer and immunolabelling was performed as in
[20]. Briefly, cells were lysed in RIPA buffer (50 mM Tris, 150 mMNaCl, 10% SDS, 1% Nonidet
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P-40, 1 mMNa3VO3, and 1 mMNaF, 0, 5% sodium deoxycolate, 1 mM phenylmethylsulfonyl
fluoride, protease inhibitor mixture, pH 8.0). Proteins were separated by sodium dodecyl sul-
fate-polyacrylamide gel electrophoresis (SDS-PAGE) on 10% acrylamide gels and blotted onto
nitrocellulose membranes. After blocking in 5% (w/v) non-fat dry milk, the membranes were
washed with 1X TWEEN-TBS and incubated with primary antibodies for overnight at 4°C. For
the detection of AMPK activity phospho-acetylCoA carboxylase (pACC) (1:500), (Cell Signal-
ing) was used. Actin was detected using a rabbit polyclonal antibody (Sigma, 1:5000). The sec-
ondary antibody was IgG peroxidase HRP conjugate (Sigma, 1:2000). Bands were visualized by
enhanced chemiluminescence reaction (West Pico ECL Kit, Thermo Scientific).
Measurement of mitochondrial membrane potential
Mitochondrial membrane potential was determined by (3,30-dihexyloxacarbocyanine iodide)
(DioC6) staining as described in [20]. MCF-7 cells were seeded in 96-well plate (25 000 cells/
well). After one or six day treatment, cells were harvested by adding trypsin/EDTA, and the
detached cells were stained with 40 nM DioC6 for 30 min) then washed with phosphate-buff-
ered saline (PBS). Cells were subjected to flow cytometric analysis (FACSCalibur, BD Biosci-
ences) with 20,000 events collected for each sample; each measurement point was repeated in
3 parallel replicates. Control cells were treated with 10 μMCarbonyl cyanide-4-(trifluoro-
methoxy)phenylhydrazone (FCCP) to dissipate mitochondrial membrane potential. The value
measured in the FCCP-treated cells were subtracted from all groups. The FCCP-corrected val-
ues were displayed and were used for statistical analysis.
RNA isolation, reverse transcription and QPCR
Total RNA was prepared using TRIzol reagent (Invitrogen) according to the manufacturer's
instructions. Two micrograms of RNA were used for reverse transcription (High Capacity
cDNA Reverse Transcription Kit, Applied Biosystems, Foster City, CA, USA). Diluted cDNA
was used for reverse transcription-coupled quantitative PCR (RT-qPCR). The qPCR reactions
were performed with the qPCRBIO SyGreen Lo-ROX Supermix (PCR Biosystems) using a
Light-Cycler 480 system (Roche Applied Science). Gene expression was normalized to the geo-
metric mean of human 36B4, 18S, and cyclophyllin values or for murine samples to the geo-
metric mean of human 36B4, GAPDH, and cyclophyllin values as in [21]. Primers are listed in
Table 1.
Oxygen consumption
Oxygen consumption was measured using an XF96 oxymeter (Seahorse Biosciences, North Bil-
lerica, MA, USA) similarly to [20]. MCF-7 cells were seeded in 96-well assay plates (~2000 cell/
well) and were treated for AICAR, MTX and AICAR+MTX for the time indicated. Oxygen
consumption rate (OCR, reflecting mitochondrial oxidation) and changes in pH, extracellular
acidification rate (ECAR, reflecting glycolysis) were recorded every 30 min to follow AICAR
and MTX effect. Data were normalized to protein content and normalized readings were
displayed.
Constructs, transfections
For silencing assays the pSUPER RNAi system was used similarly as in [22]. To create a small
hairpin RNA (shRNA)-expressing construct, double stranded DNA oligonucleotides were
cloned into the pSuper vector. The oligonucleotides (containing the siRNAsequence) were
annealed in annealing buffer (150 mMNaCl, 1 mM EDTA, 50 mMHepes, pH 8.0). The
AMPK Activation and Antimetabolite Treatment Inhibit Breast Cancer Growth
PLOS ONE | DOI:10.1371/journal.pone.0150232 February 26, 2016 4 / 16
resulting duplexes carried BglII and HindIII sites and were cloned into pSuper using these
sites, resulting a ready to transfect mammalian expression vector that directs intracellular syn-
thesis of shRNA-like transcripts. Transfections were performed each day throghout the six
days treatment using polyethylenimine (PEI) as a transfection reagent. Sequences of oligonu-
cleotides are listed in Table 2.
Database screening
The effect of AMPKα1, FOXO1 and PGC-1α expression on breast cancer survival was assessed
through the Kaplan-Meier plotter database (http://kmplot.com/analysis/ [23]) including those
Table 1. List of primers.
Forward
ACO2 (human) F: CCA GAG ACC GAC TAC CTG ACG; R. CCA CTT GTC AAA AGG CTC CAG
Aktin (human) F: GAC CCA GAT CAT GTT TGA GAC C; R: CAT CAC GAT GCC AGT GGT AC
AMPK (human) F: CAT GAA GAG GGC CAC AAT CAA; R: GCC AAA GGA TCC TGG TGA TTT
ATP5g1 (human) F: CTA AAC AGC CTT CCT ACA GCA ACT T; R: TGA ACC AGC CAC ACC AAC TGT
ATP5g1 (murine) F: GCT GCT TGA GAG ATG GGT TC; R: AGT TGG TGT GGC ATC A
Cyclophillin A
(human)
F: GTC TCC TTT GAG CTG TTT GCA GAC; R: CTT GCC ACC AGT GCC ATT ATG
Cyclophillin A
(murine)
F: TGG AGA GCA CCA AGA CAG ACA; R: TGC CGG AGT CGA CAA TGAT
FOXO1 (human) F: GTT CAT TGA GCG CTT AGA CTG; R: AAG TGT AAC CTG CTC ACT AAC CC
FOXO1 (murine) F: AAG GAT AAG GGC GAC AGC AA; R: TCC ACC AAG AAC TCT TTC CA
Fumarase (human) F: CTC GTT TTG GCC TCC GAA CG; R: TAA CTG GGG TTG GCA TGC GT
Fumarase (murine) F: CGC AGG TCA TCA AAA TTG GGC G; R: GGG CAG TGA CAA AAG GCA AAC C
GAPDH (murine) F: CAA GGT CAT CCA TGA CAA CTT TG; R: GGC CAT CCA CAG TCT TCT GG
IDH2 (human) F: GGT GGA GAT GGA TGG TGA TGA; R: GTG ATG GTG GCA CAC TTG ACT
IDH2 (murine) F: CGC CAT TAC CGA GAA CAC CAG A; R. GTG GTG TTC AGG AAG TGC TCG T
PGC-1α (human) F. AGA ATT GGC TTA TGG ATG TAC AGG; R: TTT GTT GAT CAT TTC CAG CAA
TAA T
PGC-1β (human) F: GTG CTG ACA AGA AAT AGG AGA GG; R: CTC TTC TGA ATT GGA ATC GTA GTC
18s (human) F: TCG AGG CCC TGT AAT TGG AAT; R: TCC CAA GAT CCA ACT ACG AGC TT
36B4 (human) F: CCA TTG AAA TCC TGA GTG ATG TG; R: GTC GAA CAC CTG CTG GAT GAC
36B4 (murine) F: AGA TTC GGG ATA TGC TGT TGG; R: AAA GCC TGG AAG AAG GAG GTC
doi:10.1371/journal.pone.0150232.t001
Table 2. Sequence of DNA oligonucleotides used to generate pSuper constructs. The interfering sequences are in bold.
Name Sequence (5’-3’) Structure
siPGC1α-1 sense GATCCCCAAGACGGATTGCCCTCATTTGTTCAAGAGACAAATGAGGGCAATCCGTCTTTTTTTA BglII /sense/loop/antisense/T(5)/HindII
siPGC1α-1 antisense AGCTTAAAAAAAGACGGATTGCCCTCATTTGTCTCTTGAACAAATGAGGGCAATCCGTCTTGGG HindIII/T(5)/antisense/loop/sense/BglII
siPGC1α-2 sense GATCCCCGACTATTGCCAGTCAATTAATTTCAAGAGAATTAATTGACTGGCAATAGTCTTTTTA BglII /sense/loop/antisense/T(5)/HindII
siPGC1α-2 antisense AGCTTAAAAAGACTATTGCCAGTCAATTAATTCTCTTGAAATTAATTGACTGGCAATAGTCGGG HindIII/T(5)/antisense/loop/sense/BglII
siPGC1β sense GATCCCCAGCAACTCTATGCTGACTTTCTTCAAGAGAGAAAGTCAGCATAGAGTTGCTTTTTTA BglII /sense/loop/antisense/T(5)/HindII
siPGC1β antisense AGCTTAAAAAAGCAACTCTATGCTGACTTTCTCTCTTGAAGAAAGTCAGCATAGAGTTGCTGGG HindIII/T(5)/antisense/loop/sense/BglII
FOXO1 sense GATCCCCCAGGACAATAAGTCGAGTTATTTCAAGAGAATAACTCGACTTATTGTCCTGTTTTTA BglII /sense/loop/antisense/T(5)/HindII
FOXO1 antisense AGCTTAAAAACAGGACAATAAGTCGAGTTATTCTCTTGAAATAACTCGACTTATTGTCCTGGGG HindIII/T(5)/antisense/loop/sense/BglII
AMPKα1 sense GATCCCCGTTGCCTACCATCTCATAATATTCAAGAGATATTATGAGATGGTAGGCAACTTTTTA BglII /sense/loop/antisense/T(5)/HindII
AMPKα1 antisense AGCTTAAAAAGTTGCCTACCATCTCATAATATCTCTTGAATATTATGAGATGGTAGGCAACGGG HindIII/T(5)/antisense/loop/sense/BglII
doi:10.1371/journal.pone.0150232.t002
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patients, where ER status was derived from gene expression data. Overall survival rates were
analyzed.
Statistical analysis
Significance was analyzed by Student’s t test, for multiple comparisons ANOVA test was
applied. Error bars represent ± S.E., unless noted otherwise.
Results
The joint application of AICAR and MTX inhibits MCF-7 proliferation, but
does not lead to cell death
We began our investigations with assessing the sensitivity of MCF-7 cells (a cellular model of
invasive ductal breast carcinoma) to AICAR and MTX. First, cells were treated with MTX (3–
300 μM) or AICAR treatment (100–1000 μM) or in combination (Fig 1A). Cell proliferation
was assessed through an invert microscope and on the sixth day of the assay total protein—that
corresponds to cell number—was assessed using SRB assay. When cells were treated with MTX
or AICAR alone we did not observe decreases in total protein content, however the combina-
tion of AICAR and MTX resulted in a marked decrease of total protein (Fig 1A). On day 6
10 μMMTX + 100 μMAICAR combination (abbreviated as AICAR+MTX) made a 50%
reduction in cell numbers; these AICAR and MTX concentrations were used in the subsequent
experiments.
As next step we made a time course experiment (Fig 1B). The effectiveness of AICAR+MTX
combination became evident on the third day of treatment and turned statistically significant
on day 6. To assess the dynamics of biochemical changes we made all measurements at an early
time point (1 day post treatment, short treatment) and late time point (6 days post treatment,
prolonged treatment).
An obvious reason for reduced total protein upon AICAR+MTX treatment could be cell
death. Importantly, we did not detect major increase in PI positive cells neither on day 1, nor
on day 6 (Fig 1C) or increases in caspase activity (data not shown), suggesting that increased
cell death is not the cause of reduced cell numbers, it is due to rather lower proliferation rate.
The joint application of AICAR and MTX induces AMPK that reverts
Warburg metabolism
Slowdown of proliferation may be the sign of an anti-Warburg rearrangement of metabolism.
First, we tested that AICAR indeed activates AMPK by monitoring the phosphorylation of ace-
tyl-CoA carboxylase (pACC). On day 1, similarly to the results on proliferation (Fig 1C),
AICAR alone did not induce AMPK, only when used in combination with MTX. Later, on day
6, MTX, AICAR and MTX+AICAR robustly induced AMPK (Fig 2).
AMPK activation was translated into mitochondrial activation indicated by higher DioC6
fluorescence suggesting increases in mitochondrial membrane potential (Fig 3A). On day 1 we
observed the induction of peroxisome proliferator activated receptor gamma coactivator
(PGC)-1α and forkhead transcription factor-1 (FOXO1) upon AICAR+MTX treatment (Fig
3B). In line with these, the expression of ATP5g1, a subunit of ATP synthase and isocitrate
dehydrogenase-2 (IDH2), a marker of tricarboxylic acid (TCA) cycle (Fig 3B) was induced
slightly suggesting that higher expression of PGC-1α and FOXO1 was translated into gene
expression programs supporting mitochondrial activity.
The expression of PGC-1α and FOXO1 further enhanced by day 6, furthermore, PGC-1β,
another key mitotropic regulator [24–26] boosted upon AICAR+MTX treatment (Fig 3C).
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Consequently, on day 6 enhanced expression of ATP5g1 and IDH2 in the AICAR+MTX
treated cells was exacerbated, moreover, other TCA cycle enzymes, fumarase and aconitase-2
(ACO2) were also induced (Fig 3C).
As anti-Warburg rearrangement of metabolism leads to the suppression of glycolysis [1], we
compared the rate of glycolysis and mitochondrial oxygen consumption using the Seahorse XF96
instrument. Interestingly, on day 1 in AICAR+MTX treated cells glycolysis was induced (Fig 4),
Fig 1. Combined treatment of AICAR and MTX decrease MCF-7 proliferation. (A)MCF-7 cells were seeded on 96-well culture plate at 3000–4000 cells/
well and were treated with MTX and AICAR as indicated (n = 4 for each measurement point). After 6 days in culture total protein was determined using SRB
assay. A typical experimental result is shown. (B)MCF-7 cells were seeded on 96-well culture plate at 3000–4000 cells/well and were treated with MTX and
AICAR as indicated (n = 4 for each measurement point). Seven parallel plates were made and started on the same day. Each day a plate was fixed and at the
end of the experiment total protein was determined using SRB in all plates. The measurement point day 0 represent the total protein before the beginning of
treatment. A typical experimental result is shown. (C)MCF-7 cells were seeded on 6-well culture plate at 90 000–100 000 cells/well. Cells were treated with
100 μMAICAR and 10 μMMTX for 1 and 6 days (n = 3 for each measurement point). Dead cells were stained using propidium iodine, cells were harvested
by tripsinization and were analyzed on a FacsCalibur flow cytometer. A typical experimental result is shown. * and *** indicate statistically significant
difference between control and treated cells at p<0.05 and p<0.001, respectively. All abbreviations are in the text.
doi:10.1371/journal.pone.0150232.g001
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evidenced by decreases in the ratio of oxygen consumption rate (OCR) / extracellular acidification
rate (ECAR). In contrast to that, on day 6 OCR/ECAR ratio increased in AICAR+MTX pointing
out increased mitochondrial activity and lower dependence of cells on glycolysis (Fig 4).
Taken together, treating MCF-7 cells with AICAR+MTX at early time point (i.e. day 1)
moderately induces mitochondrial metabolism, but supports glycolysis—paradoxically bring-
ing about rather pro-Warburg changes. However, protracted (i.e. day 6) AICAR+MTX treat-
ment largely induces mitochondrial oxidation and suppresses glycolysis setting off true anti-
Warburg changes.
AICAR+MTX treatment leads to G1/S and G2/M blockade
G1/S transition is under metabolic control: if cells do not possess the necessary substrates for
successful replication cell cycle, G1 to S transition is blocked [5]. Our previous data supported
an anti-Warburg rearrangement of cellular metabolism upon AICAR+MTX treatment, there-
fore we set out to analyze changes in cell cycle. Short term AICAR+MTX treatment (day 1)
reduced the number of cells in S and slightly elevated the number of cells in G2 (Fig 5). When
looking at the ratios between different cell cycle phases, it is apparent that G1/S and G2/S ratios
increase, while G1/G2 ratio remains constant suggesting G2/S and probably G1/S block. Pro-
longed AICAR+MTX treatment (day 6) showed similar changes, increased proportion of G2
cells with decreased number of cells in S phase (Fig 5) and increases in the proportions of cells
in G1 and G2 as compared to the number of cells in S—signs of simultaneous G1/S and G2/M
block in the cell cycle.
Combined treatment of SKBR-3 and 4T1 cells with AICAR and MTX
reduces cell proliferation rate in an additive fashion
All previous data were obtained on one cell line, therefore we verified our findings on two
other breast cancer cell lines, the human SKBR-3 and the murine 4T1. SKBR-3 cells, similarly
Fig 2. AMPK activation upon AICAR+MTX treatment. Activation of AMPK was determined byWestern blot
analysis of acetyl-CoA carboxylase phosphorylation (pACC) on day 1 and day 6. Actin was used as loading
control. C: control; M: MTX; A: AICAR; AM: AICAR+MTX. A typical experimental result is shown.
doi:10.1371/journal.pone.0150232.g002
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to MCF-7, were not sensitive to MTX and AICAR when administered alone, while the
AICAR+MTX combination slowed down cellular proliferation (Fig 6A) that coincided with
increases in the expression of several markers of mitochondrial oxidation (FOXO1, PGC-1α,
PGC-1β, fumarase, IDH2 and ACO2) that are the same as in the case of MCF-7 (Fig 6B).
4T1 cells were very sensitive to MTX, roughly thousand fold less MTX was already antipro-
liferative in 4T1 cells as compared to MCF-7 or SKBR-3 (Fig 6C). Despite the changes in sensi-
tivity we did observe a slightly enhanced antiproliferative effect of the 300 μMAICAR + 7.8
nMMTX or 300 μMAICAR + 15.6 nMMTX combination as compared to the individual com-
ponents alone (Fig 6C). Similarly to MCF-7 and SKBR-3 300 μMAICAR + 7.8 nMMTX treat-
ment induced slightly the expression of FOXO1, ATP5g1, fumarase and IDH2 (Fig 6D). Taken
together, the additive effect of AICAR+MTX treatment is not specific for MCF-7 but it acts
Fig 3. Activation of mitochondrial oxidation upon treatment with AICAR +MTX. (A)Mitochondrial membrane potential was measured by DiOC6
staining. MCF-7 cells were seeded in 96-well culture plate at 25 000 cells/well and were treated with MTX and/or AICAR as indicated (n = 4 for each
measurement point). On day 1 and day 6 cell were loaded with DioC6, cells were harvested by tripsinization and were analyzed on a FacsCalibur flow
cytometer. Mean of fluorescence intensity of 4 parallel samples were averaged and depicted. A typical experimental result is shown. (B-C) The expression of
a set of gene were analyzed using RT-qPCR on (C) day 1 and (D) day 6 in MCF-7 cells treated with MTX and/or AICAR (n = 4/4/4/4) as indicated. Bars
represent fold changes relative to control samples. All gene abbreviations are listed in the text. A typical experimental result is shown. *, ** and *** indicate
statistically significant difference between control and treated cells at p<0.05, p<0.01 and p<0.001, respectively.
doi:10.1371/journal.pone.0150232.g003
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similarly in other breast cancer cell lines as well. We tested two other cell lines, WM35 that is a
model for melanoma and SAOS that is a model for osteosarcoma; none of them was susceptible
to the MTX+AICAR combination (data not shown).
The inhibitory properties of the AICAR+MTX treatment can be reverted
by the silencing of mitotropic transcription factors
AICAR+MTX treatment brought about anti-Warburg alterations in metabolism and led to
G1/S and G2/M block in cell cycle. Enhanced expression of PGC-1α, PGC-1β and FOXO1 (Fig
3D) correlates with enhanced mitochondrial activity and the slowdown of proliferation sug-
gesting central role for these proteins in the antiproliferative effect of AICAR+MTX treatment.
We prepared shRNA expressing constructs targeting these proteins in order to assess their pos-
sible role.
Both short (until day 1) and long term (until day 6) silencing (transfection each day) effi-
ciently reduced the expression of target mRNA (Fig 7A). When these constructs were trans-
fected into MCF-7 cells the proliferation of the cells doubled (Fig 7B). Furthermore, reduced
cell proliferation upon AICAR+MTX treatment was abolished by the end of the 6 day treat-
ment (Fig 7B).
Expression of AMPKα1 and FOXO1 positively correlate with survival in
breast cancer
The previously performed experiments nominated AMPK and other mitotropic factors
(PGC’s, FOXO1) as possible targets in human breast cancer. To validate this possibility we
screened a publicly available cancer gene expression database, (Kaplan-Meier plotter, kmplot.
com). When comparing the lowest and the highest expression quartile, higher expression of
AMPKα1 and FOXO1 conferred significantly longer survival to the high expression quartile as
compared to the lowest expression quartile (Fig 7C). Higher expression of PGC-1α did not
confer longer survival (data not shown).
Fig 4. Changes in the ratio of glycolysis andmitochondrial oxidation upon treatment with AICAR + MTX.Rate of mitochondrial oxygen consumption
and glycolysis were assayed by Seahorse XF96 analyzer on day 1 and day 6 as described in Materials and Methods (n = 23/23/23/23). The OCR/ECAR ratio
was depicted that reflects the ratio of mitochondrial oxidation and glycolytic flux.OCR-oxygen consumption rate; ECAR-extracellular acidification rate. A
representative result is shown. *, ** and *** indicate statistically significant difference between control and treated cells at p<0.05, p<0.01 and p<0.001,
respectively.
doi:10.1371/journal.pone.0150232.g004
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Conclusions
Breast cancer cells are characterized by Warburg-type metabolism. This is well illustrated by
the observations showing that already breast cancer-initiating cells are characterized by
reduced mitochondrial activity [13], furthermore, triple negative breast cancer cells display
Warburg-type rearrangement [14] and mitochondrial uncoupling [15]. Metabolic reprogram-
ming is crucial in breast cancer cells. For example, mutations in mitochondrial DNA that
reduce mitochondrial output or enhance fatty acid synthesis support the development of breast
cancer [27,28]. Moreover, the induction of mitochondrial activity by thyroid hormone or doco-
sahexenoic acid in breast cancer cells can accentuate the efficacy of chemotherapy [17,29],
while reduced mitochondrial activity or enhanced glycolytic activity correlates with poor prog-
nosis [16,30]. Breast cancer cells reprogram the metabolism of adjacent non-cancerous stromal
cells too that is called a reverse-Warburg effect [31] that suggest poor clinical outcome in
patients [32]. Importantly, the degradation of AMPK is a key step in turning towards Warburg
Fig 5. AICAR+MTX treatment blocks the cell cycle. (A)MCF-7 cells were seeded in 6-well plate at 10 000 cells/well (n = 6/6/6/6). Cells were treated with
AICAR and/or MTX for the time indicated. Cells were fixed, permeabilized and charged with propidium iodide. DNA content was analyzed by flow cytometry.
The data on day 1 is the average of 3 parallel experiments, while the data for day 6 is the average of 2 parallel experiments. (B) The data on panel A was
further analyzed and the ratio between the different stages were calculated and depicted. The data derived from fig 5A. * indicate statistically significant
difference between control and treated cells at p<0.05.
doi:10.1371/journal.pone.0150232.g005
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metabolism [33] that is probably linked to decreases in the mitotropic tone of the energy sensor
web and consequently in mitochondrial oxidative metabolism.
Hereby, we provide evidence that the application of the AMPK activator AICAR is capable
of potentiating the antiproliferative effects of MTX. In our experiments six days long treatment
of MCF-7 cells with AICAR+MTX reduced cell numbers. Importantly, we detected low num-
bers of PI positive (dead) cells and no change in caspase activity, making decreased cellular
proliferation a likely hypothesis over the induction of cell death. Since breast cancer cells are
known to depend onWarburg-type rearrangement of metabolism [13–17,27] it was very likely
Fig 6. Combined treatment of SKBR-3 and 4T1 cells with AICAR andMTX reduces cell proliferation rate in an additive fashion. (A) SKBR-3 cells
were seeded on 96-well culture plate at 3000–4000 cells/well and were treated with MTX and AICAR as indicated (n = 4 for each measurement point). After 3
days in culture total protein was determined using SRB assay. The data is the average of 3 parallel experiments. (B) The expression of a set of gene were
analyzed using RT-qPCR on day 3 in SKBR-3 cells treated with MTX and/or AICAR (n = 6/6/6/6) as indicated. Bars represent fold changes relative to control
samples. All gene abbreviations are listed in the text. A typical experimental result is shown. (C) 4T1 cells were seeded on 96-well culture plate at 3000–4000
cells/well and were treated with MTX and AICAR as indicated (n = 4 for each measurement point). After 2 days in culture total protein was determined using
sulphorhodamine B. The data is the average of 3 parallel experiments. (D) The expression of a set of gene were analyzed using RT-qPCR on day 2 in 4T1
cells treated with MTX and/or AICAR (n = 6/6/6/6) as indicated. Bars represent fold changes relative to control samples. All gene abbreviations are listed in
the text. A typical experimental result is shown. * indicate statistically significant difference between control and treated cells at p<0.05.
doi:10.1371/journal.pone.0150232.g006
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that AMPK activation turned on mitochondrial oxidation and hence induced an anti-Warburg
rearrangement of metabolism. Indeed, protracted AICAR+MTX treatment brought about sev-
eral features of an anti-Warburg metabolic rearrangement, enhances in mitochondrial activity,
decreased glycolytic flux. AMPK activation has beneficial effects in in vivo experimental lym-
phoma models [10] or breast cancer cells other than MCF-7 (SKBR-3 and 4T1, as shown here,
or MDA-MB-231 [34]). In these models decreased lactate production, glucose uptake, replica-
tion rate and enhancement of fatty acid oxidation or oxygen consumption characterize AMPK
activation [10,34], similarly to our observations.
By providing the necessary substrates, Warburg metabolism feed forward the cell cycle [5].
The study of Colombo and colleagues [5] showed that the transition through the G1/S check-
point depends onWarburg-specific enzymes that upregulate glucose and glutamine utilization
[5,35]. A study by Beckers and colleagues [34] supports and extends these and our observations
by showing that AICAR+MTX treatment reduces the rate of DNA replication. In accordance
with that, we observed the accumulation of cells in G1 and G2 suggesting the elongation of the
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cell cycle through slower transition at the G1/S and G2/M checkpoints both on day 1 and day 6
in AICAR+MTX cells. The appearance of G2/M block was an unexpected finding for us, how-
ever, recent reports have shown that the G2 to M transition, similarly to the G1 to S transition,
also depends on cellular bioenergetics and glycolytic rate [36,37].
What is the molecular mechanism behind these effects? As expected, upon AICAR treat-
ment we observed AMPK activation. AMPK activation blunts anabolism and induces catabo-
lism, wherein increased mitochondrial oxidation and mitochondrial biogenesis has key role
[38,39]. PGC-1α, PGC-1β and FOXO1 are mitotropic transcription factors downstream of
AMPK [40–42]. Using an shRNA approach we proved that the overexpression of these master
transcription factors are crucial in the AICAR+MTX-mediated inhibition of proliferation and
the upregulation of PGCs and FOXO1 upon AMPK activation explains the upregulation of
mitochondrial activity. Importantly, an in silico approach has already nominated PGCs and
NRF1 as key proteins regulating bioenergetics in breast cancer cells [43]. Furthermore, Faubert
and colleagues [10] have shown the suppression of the HIF and mTORC1 pathway in experi-
mental lymphoma models upon AICAR treatment that may be implicated in our models too.
Hereby, we provided evidence that the joint application of MTX and AICAR is probably an
efficient combination for breast cancer chemotherapy, whereby we suggest a new partner to
potentiate the anti-proliferative effects of MTX and provided evidence for the possible applica-
bility of humans. Furthermore, the AICAR+MTX combination exert similar effects in other
cancer cells, such as in A431 cells that is a model for human squamous carcinoma [34] pointing
out the possible application of that combination in other cancers. Finally, on a wider perspec-
tive, it seems that the simultaneous induction of mitochondrial activity and modulation of an
independent metabolic pathway may induce synthetic lethality or slow down proliferation in
cancers other than breast cancer that can be later exploited in combatting the disease.
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